PH12021551685A1 - Deuterated elagolix-like compositions and methods - Google Patents
Deuterated elagolix-like compositions and methodsInfo
- Publication number
- PH12021551685A1 PH12021551685A1 PH1/2021/551685A PH12021551685A PH12021551685A1 PH 12021551685 A1 PH12021551685 A1 PH 12021551685A1 PH 12021551685 A PH12021551685 A PH 12021551685A PH 12021551685 A1 PH12021551685 A1 PH 12021551685A1
- Authority
- PH
- Philippines
- Prior art keywords
- elagolix
- deuterated
- compounds
- methods
- analogs
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- HEAUOKZIVMZVQL-VWLOTQADSA-N Elagolix Chemical compound COC1=CC=CC(C=2C(N(C[C@H](NCCCC(O)=O)C=3C=CC=CC=3)C(=O)N(CC=3C(=CC=CC=3F)C(F)(F)F)C=2C)=O)=C1F HEAUOKZIVMZVQL-VWLOTQADSA-N 0.000 abstract 4
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052805 deuterium Inorganic materials 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 206010046798 Uterine leiomyoma Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 229950004823 elagolix Drugs 0.000 abstract 1
- 230000007717 exclusion Effects 0.000 abstract 1
- 201000010260 leiomyoma Diseases 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 230000035479 physiological effects, processes and functions Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000010579 uterine corpus leiomyoma Diseases 0.000 abstract 1
- 201000007954 uterine fibroid Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962792822P | 2019-01-15 | 2019-01-15 | |
| PCT/US2020/013402 WO2020150170A1 (fr) | 2019-01-15 | 2020-01-13 | Compositions deutérées de type elagolix et méthodes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12021551685A1 true PH12021551685A1 (en) | 2022-05-16 |
Family
ID=71613236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2021/551685A PH12021551685A1 (en) | 2019-01-15 | 2020-01-13 | Deuterated elagolix-like compositions and methods |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11400093B2 (fr) |
| EP (1) | EP3911327A4 (fr) |
| JP (1) | JP2022518019A (fr) |
| CN (1) | CN113543787A (fr) |
| AU (1) | AU2020209646A1 (fr) |
| BR (1) | BR112021013908A2 (fr) |
| CA (1) | CA3126925A1 (fr) |
| MX (1) | MX2021008457A (fr) |
| PH (1) | PH12021551685A1 (fr) |
| WO (1) | WO2020150170A1 (fr) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1255738E (pt) | 2000-01-25 | 2012-06-19 | Neurocrine Biosciences Inc | Antagonistas do receptor da hormona de libertação da gonadotrofina e métodos relacionados com os mesmos |
| CN100424078C (zh) | 2003-07-07 | 2008-10-08 | 纽罗克里生物科学有限公司 | 作为促性激素释放激素受体拮抗剂的嘧啶-2,4-二酮衍生物 |
| US8765948B2 (en) | 2007-11-07 | 2014-07-01 | Neurocrine Biosciences, Inc. | Processes for the preparation of uracil derivatives |
| EP3185881B1 (fr) * | 2014-08-26 | 2022-03-09 | Betanien Hospital | Méthodes, agents et compositions pour le traitement d'états inflammatoires |
| AU2016317955B2 (en) * | 2015-09-01 | 2021-05-20 | Abbvie Inc. | Methods of administering Elagolix |
| WO2017221144A1 (fr) | 2016-06-20 | 2017-12-28 | Dr. Reddy's Laboratories Limited | Procédé de préparation d'élagolix sodique et de son polymorphe |
| WO2018198086A1 (fr) | 2017-04-28 | 2018-11-01 | Lupin Limited | Procédé de préparation d'élagolix et de ses sels pharmaceutiquement acceptables |
| WO2018224063A2 (fr) | 2017-06-08 | 2018-12-13 | Zentiva, K.S. | Formes à l'état solide d'élagolix |
| CN108129400B (zh) | 2017-12-29 | 2021-10-15 | 安帝康（无锡）生物科技有限公司 | 氘代噁拉戈利衍生物及其用途 |
-
2020
- 2020-01-13 PH PH1/2021/551685A patent/PH12021551685A1/en unknown
- 2020-01-13 US US16/741,677 patent/US11400093B2/en active Active
- 2020-01-13 MX MX2021008457A patent/MX2021008457A/es unknown
- 2020-01-13 WO PCT/US2020/013402 patent/WO2020150170A1/fr not_active Ceased
- 2020-01-13 CA CA3126925A patent/CA3126925A1/fr active Pending
- 2020-01-13 CN CN202080018761.3A patent/CN113543787A/zh active Pending
- 2020-01-13 EP EP20741599.3A patent/EP3911327A4/fr not_active Withdrawn
- 2020-01-13 BR BR112021013908-7A patent/BR112021013908A2/pt not_active Application Discontinuation
- 2020-01-13 AU AU2020209646A patent/AU2020209646A1/en not_active Abandoned
- 2020-01-13 JP JP2021541235A patent/JP2022518019A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022518019A (ja) | 2022-03-11 |
| AU2020209646A1 (en) | 2021-08-26 |
| EP3911327A1 (fr) | 2021-11-24 |
| CN113543787A (zh) | 2021-10-22 |
| WO2020150170A1 (fr) | 2020-07-23 |
| BR112021013908A2 (pt) | 2021-09-21 |
| US20200268756A1 (en) | 2020-08-27 |
| EP3911327A4 (fr) | 2022-10-26 |
| US11400093B2 (en) | 2022-08-02 |
| CA3126925A1 (fr) | 2020-07-23 |
| MX2021008457A (es) | 2021-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202100208B (en) | Heterocyclic and heteroaryl compounds for treating huntington's disease | |
| JOP20220130B1 (ar) | مجموعات تترا هيدروفيوران بها استبدال في صورة عوامل تعديل لقنوات الصوديوم | |
| PH12020551578A1 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
| MX2019015580A (es) | Metodos para tratar la enfermedad de huntington. | |
| MX2019011530A (es) | Saxitoxinas 11,13-modificadas para el tratamiento del dolor. | |
| JOP20220092A1 (ar) | جسم مضاد لبيتا-النشواني لعلاج مرض الزهايمر | |
| ZA202006137B (en) | Substituted imidazolidin-2-one derivatives as prmt5 inhibitors | |
| MX2019015578A (es) | Metodos para tratar la enfermedad de huntington. | |
| MY189194A (en) | Substituted tetrahydroquinolinone compounds as ror gamma modulators | |
| JOP20210323A1 (ar) | ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3 | |
| PH12018502438A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| PH12020552092A1 (en) | Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease | |
| NZ756231A (en) | A novel isoindoline derivative, a pharmaceutical composition and use thereof | |
| MX2022006807A (es) | Análogos de rapamicina y usos de estos. | |
| CR20190433A (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
| NZ754764A (en) | Pyrimidine tricyclic enone derivatives for inhibition of rorγ and other uses | |
| GEP20247585B (en) | Furoindazole derivatives | |
| MX2024001417A (es) | Compuestos de heteroarilo para tratar la enfermedad de huntington. | |
| NZ786543A (en) | Compounds active towards nuclear receptors | |
| PH12019501724A1 (en) | Estrogen receptor modulators | |
| ZA202107777B (en) | Voruciclib polymorphs and methods of making and using thereof | |
| MX2019013562A (es) | Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos. | |
| TN2018000214A1 (en) | Alkyl dihydroquinoline sulfonamide compounds | |
| MX2021013391A (es) | Conjugado de anticuerpo anti-bcma, composiciones que comprenden el mismo, y metodos de fabricacion y uso del mismo. | |
| PH12021551685A1 (en) | Deuterated elagolix-like compositions and methods |